ANDA 76395, held by Apotex. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 76395 (Diltzac), held by Apotex, was first approved by FDA on Feb 1, 2006, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 1, 2006 | Original application | Approved | None posted |
| Diltzac120MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Diltzac180MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Diltzac240MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Diltzac300MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Diltzac360MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Jul 10, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jul 10, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 24, 2012 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 9, 2008 | Supplement 5Labeling | Approved | None posted |
| Feb 1, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters